ClinicalTrials.gg
TerminatedNCT01464593ABLATEUpdated Oct 13, 2022Results posted

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

A Phase 2 interventional study of Lyso-Thermosensitive Liposomal Doxorubicin and 5% Dextrose Solution in Colon Cancer Liver Metastasis, sponsored by Imunon. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-13.

Sponsored by Imunon · Phase 2, Interventional, and Treatment

Why this study was terminated
trial design contingent on RFA optimization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,121 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Enrollment
807th of 863
2 · median 50
Started
2011
with 38 others
Phase 2
226 of 1,121
16 open now
Registered
568th of 1,121
by date

Among the 1,121 studies in Colonic Neoplasms with a site in United States, this one is the 807th largest by enrollment of the 863 interventional ones that give a count, is one of 39 that started in 2011, is one of 226 in phase 2, and was the 568th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

115 of the 1,121 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,121 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of Thermodox, a thermally sensitive liposomal doxorubicin, in combination with thermal ablation in the treatment of hepatic colorectal liver metastases (CRLM).

Read the detailed description

This is an open label phase II trial to evaluate the safety, feasibility, and efficacy of ThermoDox in combination wtih thermal ablation for the regional hepatic treatment of mCRC liver lesions.

Eligible colorectal cancer patients will unresectable liver metastases and be candidate for either radiofrequency ablation (RFA) or microwave ablation (MWA). All unresectable lesions must be targeted for ablation in in nor more than 2 thermal ablation/ThermoDox procedures.

Approximately 24 hours prior to treatment with ThermoDox, patients will start a regimen of prophylaxis (detailed in the Study Drug section below) against immediate hypersensitivity reactions.

Treatment will begin with a 50 mg/m2 ThermoDox infusion administered intravenously (IV) over 30 minutes. Thermal Ablation will be initiated a minimum of 15 minutes after start of the infusion and should be completed no later than 3 hours after starting the infusion. Subjects will have follow up visits on Day 14 and at months 1, 4, 7, 10,13, 16, 19, 22, and 25 (+ 7 days) or until study discontinuation.

At baseline and at each post-treatment clinic visit, patients will self-report their "quality of life" (QoL) using the 8-item FACT-Hepatobiliary Symptom Index (FHSI-8).

Contrast CT imaging studies or Magnetic Resonance Imaging (MRI)will be used to assess the effectiveness of therapy. CT or MRI scans will be obtained at baseline and at months 1, 4, 7, 10, 13, 16, 19, 22, and 25(+ 7 days)until local recurrence is seen, the subject has discontinued, or 2 years of follow-up have elapsed, whichever occurs first. All protocol-specified CT/MRI images will be centrally read by an independent radiology assessor.

Subjects will be followed for each efficacy endpoint local tumor control through 2 years after treatment. Secondary endpoints including Overall Survival, Time to Local Recurrence, PRO deterioration) will be evaluated until the event occurs, the subject is discontinued, or until 3 years following treatment.

03

Conditions studied

  • Colon Cancer Liver Metastasis

Keywords

  • Colorectal Liver Metastasis
  • Colon Cancer
  • Liver Cancer
  • Liver Metastasis
  • Liver metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathologic diagnosis of colorectal cancer.
  2. A minimum of 1 unresectable mCRC liver lesion at baseline clinically indicated for radiofrequency ablation (RFA) or microwave ablation (MWA).

    • Recurrent lesions may have been treated previously by resection or ablation.
    • Anticipated ablation volume will be no larger than either removal of 3 hepatic segments or removal of more than 30% of total liver volume (as per maximum surgical limit).
    • Patients may have resectable lesions that are treated surgically.
    • If additional lesions are discovered during the ablation treatment procedure that were undetectable at screening will be treated at the discretion of the physician and guided by local standard of care.
    • Confirm the lesions are malignant by a pretreatment or by a biopsy obtained during the ablation procedure.
  3. Subjects with suspected or limited extra-hepatic mCRC are eligible provided thermal ablation is clinically indicated. Chemotherapy is not permitted within 5 half-lives or 30 days if shorter prior to initial study treatment through 30 days following final study treatment.
  4. Male or female 18 years of age or older.
  5. Are willing to sign an form.
  6. (LVEF) ≥ 50%
  7. Willing to return to the study site for study visits.
  8. Have performance status ≤ 2 and of ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant bowel surgery and/or synchronous colon resection.
  2. Have serious illnesses including, but not limited to, congestive heart failure;life threatening cardiac arrhythmia; or myocardial infarction or cerebral vascular accident within the last 6 months.
  3. Have previously received any doxorubicin (study subjects being considered for completion of treatment may have received ThermoDox previously).
  4. Are pregnant or breast-feeding. In women of , a negative pregnancy test (serum) is required within 14 days prior to study treatment.
  5. Women and men of childbearing potential who are not practicing an acceptable form of (i.e. diaphragm, cervical cap, condom, surgical sterility or birth control pills.
  6. Have any known allergic reactions to any of the drugs or liposomal components or intravenous imaging agents to be used in this study.
  7. Have portal or hepatic vein tumor invasion/thrombosis.
  8. Have > 1.5 times the institution's upper normal limit (UNL), except in subjects who are therapeutically anticoagulated for medical conditions unrelated to CRLM such as atrial fibrillation. Subjects may be re-screened after condition is treated or anticoagulant is withheld.
  9. Have count \< 75,000/mm3, \< 1500/mm3, or \< 10.0 g/dL (unless the hemoglobin value has been stable, the subject is cardiovascularly stable, asymptomatic, and judged able to withstand the RFA procedure).
  10. Have serum creatinine ≥ 2.5 mg/dL or calculated (CrCl) ≤ 25.0 mL/min.
  11. Have serum > 3.0 mg/dL.
  12. Have serum albumin \< 2.8 g/dL.
  13. Have body temperature > 38.3°C immediately prior to study treatment.
  14. Have to receiving doxorubicin HCl.
  15. Are being treated with other agents or use of an investigational agent within 5 half-lives or 30 days whichever is longer preceding the first dose of study medication.
  16. Use of chemotherapy within 5 half-lives or 30 days, whichever is shorter, preceding the first dose of study medication and no chemotherapy planned for 30 days after ablation(s).
  17. Have concurrent other than mCRC (subjects wtih treated squamous cell carcinoma of the skin or basal cell carcinoma of the skin maybe included) or ongoing medically significant active infection.
  18. Documented positive.
  19. class III or IV functional classification for heart failure.
  20. Evidence of hemochromatosis.
  21. Have history of contrast induced nephropathy and unable to undergo MRI.
  22. Have a history of Nephrogenic Systemic Fibrosis (NSF).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Thermodox

    Thermodox 50 mg/m2 intravenous infusion over 30 minutes starting 15 minutes before thermal ablation.

    Drug: Lyso-Thermosensitive Liposomal Doxorubicin · Other: 5% Dextrose Solution · Drug: ThermoDox

Interventions

  • Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.

    Also known as: Liposomal doxorubicin, Doxorubicin, Thermodox

  • Other5% Dextrose Solution

    Single 30 minute intravenous infusion

  • ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.

06

What researchers measure

Primary outcomes

  1. Determine the Local Tumor Control at 1 Year Post Randomization

    Subject's treated with thermal ablation in conjunction with Thermodox to evaluate local tumor control defined as complete ablation and does not experience recurrence within 1 cm of the ablation site.

    Time frame: 1 year

Secondary outcomes

  1. Evaluation of Safety

    Adverse events will be assessed through 1 month following study treatment(s). AE's after 1 month through the Month 25 assessment are reported if possibly, probably, or definitely related to study drug. Safety data will include physical exams, vital signs, ECGs, Echocardiograms/MUGA Scans, hematology, clinical chemistry and urinalysis.

    Time frame: 1 month

  2. Time to Local Recurrence

    Measured as the time to local recurrence after ablation as measured from the date of randomization.

    Time frame: 2 years

  3. Overall Survival

    Measured as time from randomization to death or the end of the study at month 37.

    Time frame: 3 years

07

Results

Posted Oct 13, 2022

Participant flow

Participant flow — Overall Study
MilestoneThermodox
Started1
Completed0
Not completed1
Withdrew: Study terminated early due to lack of enrollment1

Outcome measures

PrimaryDetermine the Local Tumor Control at 1 Year Post Randomization

Subject's treated with thermal ablation in conjunction with Thermodox to evaluate local tumor control defined as complete ablation and does not experience recurrence within 1 cm of the ablation site.

Time frame:
1 year

No measurements were reported for this outcome.

SecondaryEvaluation of Safety

Adverse events will be assessed through 1 month following study treatment(s). AE's after 1 month through the Month 25 assessment are reported if possibly, probably, or definitely related to study drug. Safety data will include physical exams, vital signs, ECGs, Echocardiograms/MUGA Scans, hematology, clinical chemistry and urinalysis.

Time frame:
1 month

No measurements were reported for this outcome.

SecondaryTime to Local Recurrence

Measured as the time to local recurrence after ablation as measured from the date of randomization.

Time frame:
2 years

No measurements were reported for this outcome.

SecondaryOverall Survival

Measured as time from randomization to death or the end of the study at month 37.

Time frame:
3 years

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Thermodox0/1 (0%)0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Thermodox
Mean41
Sex: Female, Male
Sex: Female, Male(Participants)Thermodox
Female0
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Thermodox
Hispanic or Latino0
Not Hispanic or Latino1
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Thermodox
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Thermodox
United States1
08

Study locations

4 sites
  • UCLA
    Los Angeles, California 90095, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Cleveland Clinic Hospital
    Cleveland, Ohio 44195, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of May 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2022, 9 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2011
First posted
Nov 3, 2011
Start
Sep 2011
Primary completionActual
May 2013
CompletionActual
Jun 2013
Results first posted
Oct 13, 2022
Last update
Oct 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01464593
Lead sponsor
Imunon
Responsible party
Sponsor
First posted
Nov 3, 2011
Start date
Sep 2011
Primary completion
May 2013
Completion
Jun 2013
Results posted
Oct 13, 2022
Last update
Oct 13, 2022

Study contacts

Nicholas Borys, M.D.
study director · Imunon

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal doxorubicin · Lyso-Thermosensitive Liposome Doxorubicin

Start the discussion